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Background: Cytokine-induced killer (CIK) cells are an emerging approach of cancer treatment. Our previous study
have shown that CIK cells stimulated with combination of IL-2 and IL-15 displayed improved proliferation capacity
and tumor cytotoxicity. However, the mechanisms of CIK cell proliferation and acquisition of cytolytic function
against tumor induced by IL-2 and IL-15 have not been well elucidated yet.
Methods: CIKIL-2 and CIKIL-15 were generated from peripheral blood mononuclear cells primed with IFN-γ, and stimulated
with IL-2 and IL-15 in combination with OKT3 respectively. RNA-seq was performed to identify differentially expressed genes,
and gene ontology and pathways based analysis were used to identify the distinct roles of IL-2 and IL-15 in CIK preparation.
Results: The results indicated that CIKIL-15 showed improved cell proliferation capacity compared to CIKIL-2. However, CIKIL-2
has exhibited greater tumor cytotoxic effect than CIKIL-15. Employing deep sequencing, we sequenced mRNA transcripts in
CIKIL-2 and CIKIL-15. A total of 374 differentially expressed genes (DEGs) were identified including 175 up-regulated genes in
CIKIL-15 and 199 up-regulated genes in CIKIL-2. Among DEGs in CIKIL-15, Wnt signaling and cell adhesion were significant GO
terms and pathways which related with their functions. In CIKIL-2, type I interferon signaling and cytokine-cytokine receptor
interaction were significant GO terms and pathways. We found that the up-regulation of Wnt 4 and PDGFD may contribute
to enhanced cell proliferation capacity of CIKIL-15, while inhibitory signal from interaction between CTLA4 and CD80 may be
responsible for the weak proliferation capacity of CIKIL-2. Moreover, up-regulated expressions of CD40LG and IRF7 may make
for improved tumor cytolytic function of CIKIL-2 through type I interferon signaling.
Conclusions: Through our findings, we have preliminarily elucidated the cells proliferation and acquisition of tumor
cytotoxicity mechanism of CIKIL-15 and CIKIL-2. Better understanding of these mechanisms will help to generate novel CIK
cells with greater proliferation potential and improved tumor cytolytic function.
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Cancer is still a leading cause of diseases related death
all over the world. It was estimated that 7.6 million
people were dead from various types of cancer in 2008,
and the figure will continue to rise to 13.1 million in
2030 [1]. Fortunately, significant progress has been made
to develop better approaches to prevent, diagnose and* Correspondence: hzl579@163.com; lrh272@yahoo.com
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unless otherwise stated.treat cancer in the past several years. These advances
have made more people survive with their cancer today.
However, these new approaches are not completely ef-
fective to all of cancers, and side effects were brought by
some of treatments. Among these advances, immuno-
therapy has shown its large potential in cancer therapy.
Cytokine-induced killer (CIK) cells, a subset of T lym-
phocytes with a natural killer T cell phenotype, have
been proven to be effective to most of tumors in vitro
and in vivo [2]. CIK cells exhibit potent cytolytic activ-
ities against tumor cells with minimal adverse effects.
CIK cells are prepared from peripheral blood mononucleartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with monoclonal antibody against CD3 (OKT3) and
interleukin-2 in the following days [3]. During the gen-
eration of CIK cells, monoclonal antibody against CD3
provided mitogenic signals to T lymphocytes. Priming
with IFN-γ is to activate the monocytes which provide
contact-dependent (CD58/LFA-3) and soluble (IL-12)
crucial signals promoting generation of autophagy and
antigen cross-presentation [4]. In following bulk cul-
ture, IL-2 promotes T cell proliferation, survival and
acquisition of cytolytic effector function.
IL-15 is a cytokine which stimulate growth of NK,
NKT cells and activated T lymphocytes in peripheral,
and it has similar biological properties with IL-2 in in-
nate immunity [5]. Studies have suggested that IL-15
bind to subunits of IL-2 receptor and common gamma
chain [6]. Because IL-15 and IL-2 share common signal-
ing components, they mediate a series of similar signal-
ing events. These events include activation of the Janus
kinase (Jak) and STAT pathways. The two cytokines
both can facilitate the induction of tumor toxic effector
T cells and proliferation of NK cells. However, IL-15 and
IL-2 are differed in their cDNA/protein sequence and
contribute differently to T cell-mediated immune re-
sponse [6]. Although IL-2 is a growth and survival factor,
it plays important role in Fas-mediated activation-
induced cell death (AICD) of CD4 T cell. In contrast,
IL-15 promotes the survival of T lymphocytes by inhi-
biting IL-2-mediated CD4+ T cell AICD [7].
In our previous study, we have shown that CIK cells
stimulated with combination of IL-2 and IL-15 exhibited
enhanced cytotoxic capacity against lung cancer both
in vitro and in vivo. Interestingly, we found that CIK
cells activated with IL-2 and IL-15 could up-regulate the
expression levels of IFN-γ and TNF-α in vivo compared
to CIK cell stimulated with IL-2 alone [8]. In order to
identify the roles of IL-2 and IL-15 during induction of
tumor toxic function of CIK cells, we performed com-
parative transcriptome analysis between CIK cells pre-
pared with IL-15 and IL-2 respectively by Ion PI mRNA
sequencing (RNA-seq) for the first time. The mRNAs
isolated from CIKIL-15 cells and CIKIL-2 cells were tran-
scribed into cDNAs which were applied to deep sequen-
cing. The results of RNA-seq were analyzed by a series
of bioinformatic methods including mapping, gene dif-
ferential expression analysis, gene ontology (GO) and
pathway analysis. Our finding will provide evidence for
optimizing the CIK cell propagation strategy which pro-
duces more effective CIK cells against tumor.
Methods
Cell lines and reagents
Human lung adenocarcinoma (SPC-A-1 cells) and gas-
tric tumor cells (BGC823) were obtained from ChineseType Culture Collection (Shanghai, PR China). FITC
conjugated anti-CD56 antibody and R-phycoerythrin
conjugated anti-CD3 antibody used in identifying CIK
phenotypic markers were purchased from BD Biosci-
ences. The cell viability assay kit (Cell Counting Kit-8)
was purchased from Dojindo, Molecular Technologies.
Reagents for CIK cells generation including OKT3, IFN-γ,
IL-2 and IL-15 were from Miltenyi Biotec. Experiments
involving human peripheral blood were reviewed and ap-
proved by Bioethics Committee of Yan’an Affiliated Hos-
pital of Kunming Medical University. Written informed
consents have been given from all volunteers participated
in this study.
Generation of CIKIL-2 and CIKIL-15 (Standard protocols)
The Bioethics Committee of Yan’an Affiliated Hospital
of Kunming Medical University has approved the inves-
tigation protocols to draw blood from healthy volunteers
after written informed consent for the purposes of prepar-
ation CIK cells against tumor and deep sequencing. CIK
cells were prepared from PBMCs which were isolated by
standard Ficoll separation. PBMCs were cultured in RPMI
1640 growth medium at a density of 5 × 106 cells/mL. The
RPMI 1640 growth medium for CIK contained 10% FBS,
2% L-glutamine and antibiotics. The generation of CIK cells
was primed by adding 1000 U/mL IFN-γ on day 0 and
100 ng/mL anti-CD3 antibody and 500 U/mL IL-2 or
10 ng/mL IL-15 within the following 15 days of culture.
The CIK cells were propagated every 5 days with RPMI
1640 growth medium supplemented with anti-CD3 anti-
body and IL-2 or IL-15 respectively [9]. The CIK cells
were expanded for 15 days and analyzed every 5 days.
Cytotoxicity assay based on CCK-8
After co-culture with CIK cells for 48 hours, the cell viabil-
ities of two tumor cells were determined by CCK-8 based
methods. Briefly, 10uL of CCK-8 solution was added in each
well, and the plates were incubated at 37°C for 2–4 hours.
After incubation, the absorbance of each well was read by a
spectrophotometer at 450 nm. Each sample for one treat-
ment was calculated by values from 5 independent samples.
RNA extraction and quality control
Total RNA was extracted from each sample using TRIzol
Reagent (Life technologies, USA) according to the proto-
col from manufacturer. The concentration of each sample
was measured by NanoDrop 2000 (Thermo Scientific,
USA). The quality was assessed by the Agilent2200
(Agilent, USA).
Whole transcriptome libraries preparation and deep
sequencing
The sequencing library of each RNA sample was pre-
pared by using Ion Total RNA-Seq Kit v2 according to
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USA). Briefly, poly(A)-containing mRNA was purified
from 5 ug total RNA with Dynabeads (Life technologies,
USA). The mRNA was fragmented using RNaseIII and
purified. The fragmented RNA was hybrized and ligated
with Ion adaptor. The RNA fragments were reverse-
transcribed and amplified to double-stranded cDNA.
Then, the amplified cDNA was purified by magnetic
bead based method, and the molar concentration was
determined for each cDNA library. Emulsion PCR was
performed using template of cDNA library. The Template-
Positive Ion PITM Ion SphereTM Particles were enriched
and loaded on the Ion PITM chip for sequencing.
Filtering raw reads and mapping
The raw reads ≥50 bp which passed filtering were used
for mapping. We used the Masplicing as our RNA-seq
data mapping analysis tool whose core program is Bow-
tie that can identify the exon-exon splicing immediately
and accurately [10].
Identification of differentially expressed genes
We applied the DEseq to filter the differentially expressed
genes for the CIKIL-15 and CIKIL-2 groups. After the statis-
tical analysis, we selected the differentially expressed genes
according to the FDR threshold (FDR < 0.05) [11].
GO analysis
GO analysis was applied to analyze the main function of
the differential expression genes according to the Gene
Ontology which is the key functional classification of
NCBI [12,13]. Generally, Fisher’s exact test and χ2 test
were used to classify the GO category, and the false dis-
covery rate (FDR) was calculated to correct the P-value,
the smaller the FDR, the small the error in judging the
p-value [14,15]. The FDR was defined as FDR ¼ 1− NkT ,
where Nk refers to the number of Fisher’s test P-values
less than χ2 test P-values. We computed P-values for the
GOs of all the differential genes. The significant GO
terms were defined as P value <0.05 and FDR <0.05.
Concerning on the treatment of GO term redundancy,
we have adopted strategy of filtering out terms by pick-
ing only one from each leaf-to-root path.
Pathway analysis
Similarly, pathway analysis was used to find out the sig-
nificant pathway of the differential genes according to
KEGG, Biocarta and Reactome [10,16,17]. Still, we turn
to the Fisher’s exact test and χ2 test to select the signifi-
cant pathway, and the threshold of significance was de-
fined by P-value and FDR. The significant pathway was
identified by P value <0.05 and FDR < 0.05. The enrich-
ment was calculated like the equation above [18-20].Gene-act-network
Use the KEGG database to build the network of genes
according to the relationship among the genes, proteins
and compounds in the database [21-25].
Path-act-network
KEGG database has included metabolism, membrane
transport, signal transduction, cell cycle pathways and
information about interactions among them. The genes
we have selected may involved in two or more signaling
pathways. Because of the same genes in different path-
ways, overlappings between pathways were obvious. We
picked the genes in enriched biological pathway and
used Cytoscape for graphical representations of path-
ways [26].
Co-expression network analysis
For each pair of genes, we calculate the Pearson Correl-
ation and choose the significant correlation pairs (FDR <
0.01) to construct the network [27]. Within the network
analysis, degree centrality is the most simplest and im-
portant measures of the centrality of a gene within a net-
work that determine the relative importance. Degree
centrality is defined as the link numbers one node has to
the other [28]. Moreover, to study some properties of the
networks, k-cores in graph theory were introduced as a
method of simplifying graph topology analysis [29].
Quantitative reverse-transcription PCR
All the qRT-PCR involved in this study was performed
on the CFX96 Touch™ (BIORAD, USA). The first strand
of cDNA was synthesized with adjusted concentration of
RNA, and corresponding genes were amplified by employ-
ing EVA Green Supermix. All the primers used for qRT-
PCR were obtained from GeneCopoeia (USA).
Results
Enhanced cell proliferation capacity of CIKIL-15 and
superior tumor toxic effect of CIK IL-2
CIK cells were generated from peripheral blood mono-
nuclear cells of three healthy volunteers. The CIKIL-15
and CIKIL-2 cells were confirmed by flow cytometry with
the phenotypes of CD3+CD56+. The results have demon-
strated that the percentages of CD3+CD56+ cells were
98.80 ± 0.503% and 97.60 ± 0.603% respectively in CIKIL-2
and CIKIL-15 (Figure 1A). We determined the proliferation
capacities of CIKIL-15 and CIKIL-2 by automatic cell count-
ing. The result showed that CIKIL-15 displayed significantly
higher proliferation capacity than CIKIL-2 (Figure 1B). To
evaluate the tumor toxic effects of CIKIL-15 and CIKIL-2,
we have chosen two types of tumor cell lines including
human gastric tumor (BGC823) and human lung adeno-
carcinoma (SPC-A-1) as the targets in anti-tumor assay.
After co-culture with CIKIL-15 and CIKIL-2 for 48 hours,
Figure 1 A overview of phenotypes, functions and RNA-seq quality control of CIKIL-15 and CIKIL-2. (A) Flow cytometric and statistical
analysis of the proportion of CD3+CD56+ CIK cells. Numbers indicate the percentage of each subset. (B) Cell proliferation capacity assay of CIKIL-15
and CIKIL-2 based on automatic cell counting; (C) Detection of tumor cytotoxic effect of CIKIL-15 and CIKIL-2 against SPC-A-1 and BGC823; (D) Distribution
of reads on chromosomes; (E) Percentage of mapped reads onto the regions of exons, introns, 5’-UTR, 3’-UTR, transcription start site (TSS), transcription
end site (TES) and intergenic region.
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tumor based on CCK-8 method. The results indicated
that CIKIL-2 cells have shown greater cytotoxic poten-
tial against tumor than CIKIL-15 (Figure 1C). In order
to investigate the distinct roles of IL-2 and IL-15 in
CIK cell generation, we performed transcriptome-wide
analysis of CIKIL-2 (n = 3) and CIKIL-15 (n = 3) by deep
sequencing.
Overview of sequencing data of RNA-seq analysis
Total raw reads among the six samples ranged from 19
to 34 million. The average of the GC content is approxi-
mately 49% for each sample. By a stringent quality
check, more than 95% of the reads we obtained have a
quality score of ≧Q20. The sequencing quality was ana-
lyzed by using RSeQC [30]. The raw sequence data have
yielded about 2.2 gigabases (GB) of data per sample.
About 1.58 ± 0.48 × 107 reads (73.5% of the total raw
reads) were mapped to human genome sequence in thesix independent samples (Table 1) and 1.49 ± 0.48 × 107
reads (69.5% of the total raw reads) were uniquely
aligned to human genome. The mapping of the reads
was performed by using MapSplice. Mapped reads in six
independent samples were distributed consistently on
the chromosomes (Figure 1D). We found that chromo-
some 1 has been matched the most reads and the least
reads were found in chromosome Y. In the uniquely
mapped reads, more than 50% of the reads were aligned
at the transcript exon, 17% at the intron regions, 13% at
the UTR regions and the remaining at TES (transcrip-
tion end site), TSS (transcription start site) and inter-
genic regions (Figure 1E). Subsequently, we analyzed the
aligned reads for transcript assembly, abundance evalu-
ation and normalization. After annotation, there were
3,6267 transcripts annotated with known function
Additional file 1. In order to quantify the expression
levels of the transcripts, the RNA-seq data was normal-
ized to RPKM values.
Table 1 Statistics of raw and mapped reads from RNA-seq analysis of CIK cells stimulated by IL-15 and IL-2 respectively
CIKIL-15-1 CIKIL-15-2 CIKIL-15-3 CIKIL-2-1 CIKIL-2-2 CIKIL-2-3
Raw reads 19810412 19235209 21693091 22108193 24539599 21801487
Unmapped reads 5198537 4707536 5509521 6426050 6846138 5934418
Mapped reads (Rate) 14611875 (0.74) 14527675 (0.76) 16183570 (0.75) 15682144 (0.71) 17693461 (0.72) 15867070 (0.73)
Unique mapping (Rate) 13874295 (0.70) 13786260 (0.72) 15299443 (0.71) 14820672 (0.67) 16748163 (0.68) 15024084 (0.69)
Repeat mapping 737580 741413 884127 861471 945298 842985
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and GO analysis
To characterize the functional consequences of gene ex-
pression changes induced by IL-15 and IL-2, we screened
the differentially expressed genes (DEGs) between CIKIL-15
cells and CIKIL-2 cells by the following criteria: Log2FC > 1
or Log2FC < −1, FDR < 0.05 and P value < 0.05. We found
374 DEGs between CIKIL-15 and CIKIL-2 Additional file 2.
Of these DEGs, 175 and 199 genes were up-regulated in
CIK cells activated by IL-15 and IL-2 respectively. We used
hierarchical cluster analysis to compare the DEGs between
these two types of CIK cells and similarity of expression
patterns of three biological replicates (Figure 2). To identify
the functions of these DEGs, we performed gene onto-
logical analysis based on GO database Additional file 3.
Among these DEGs which were up-regulated in CIKIL-15,
there were 11 genes involved in cell adhesion and 5 genes
involved in Wnt signaling pathway (Figure 2). By analyzing
the significant GO terms, we found that T cell receptor V
(D)J recombination, cell adhesion and alpha-beta T cell dif-
ferentiation were involved (Figure 3A). In order to target
the DEGs which may cause functional changes, we
screened DEGs whose GO terms were closely related
with the functions of CIK cells. Based on the func-
tional assay, CIKIL-15 cells have shown greater prolifer-
ation capacity than CIKIL-2 cells in vitro. Interestingly,
we found that Wnt 4 was significantly up-regulated in
CIKIL-15 compared to CIKIL-2 (Table 2). By gene onto-
logical analysis, Wnt 4 is involved in multiple bio-
logical processes including Wnt signaling pathway,
immature T cell proliferation and negative regulation
of apoptosis (Table 2). Platelet-derived growth factor D
(PDGFD) is a growth factor that plays an essential role
in cell proliferation and survival. The expression of
PDGFD is up-regulated after stimulation of IL-15. There-
fore, we speculated that the enhanced proliferation cap-
acity of CIKIL-15 may be brought by up-regulation of
Wnt4 and PDGFD. Interleukin 21 receptor, which has
played important role in natural killer cell activation and
cytokine signaling pathway was found highly expressed in
CIKIL-15. Moreover, E3 ubiquitin protein ligase (DTX4)
and intercellular adhesion molecule (ICAM4) were also
up-regulated in CIKIL-15. These proteins may be involved
in type I interferon production and cell adhesion. Among
the DEGs in CIKIL-2, there were 17 genes participated ininnate immune response, 16 genes involved in cytokine-
mediated signaling pathway and 12 genes involved in type
I interferon signaling pathway (Figure 2). By analyzing the
significant go terms, we found that type I interferon sig-
naling pathway, cytokine-mediated signaling pathway and
immune response are significant GO terms in response to
stimulation of IL-2 (Figure 3B). Compared to CIKIL-15,
CIKIL-2 has shown enhanced cytotoxic capacity against
tumor. Consistently, we have found 3 tumor suppressive
genes which were significantly up-regulated in CIKIL-2 in-
cluding tumor necrosis factor ligand superfamily member
10 (TNFSF10), CD40 ligand (CD40LG) and interferon
regulatory factor 7 (IRF7) (Table 3). These genes were
widely involved in positive regulation of apoptotic signal-
ing pathway, potent anti-tumor effect and promote type I
interferon production. Surprisingly, we found that CD80
and its inhibitory ligand CTLA4 were co-upregulated in
CIK cells after activation of IL-2. The function of CD80 is
mainly involved in the costimulatory signal for T lympho-
cyte activation. CTLA4 functions as a negative regulator of
T cell activation, which may inhibit the T cell proliferation.
Pathways analysis of CIKIL-15 and CIKIL-2
To further identify the influence of DEGs on the func-
tions of these two types of CIK cells, we performed path-
way analysis of DEGs based on KEGG database using
Fisher exact test Additional file 4. Among DEGs of
CIKIL-15, there 5 genes participated in focal adhesion in-
cluding collagen type VI alpha 3 (COL6A3), collagen
alpha-2(VI) chain (COL6A2), collagen alpha-1(VI) chain
(COL6A1), Platelet-derived growth factor D (PDGFD)
and Myosin light chain kinase family member 4 (MYLK4)
(Figure 4A). Surprisingly, 3 genes coding collagens were
involved in this pathway which may be related with en-
hanced cell proliferation capacity of CIKIL-15. In CIKIL-2,
the results indicated that 13 genes participated in
cytokine-cytokine receptor interaction (Figure 4B). Of
these genes, IL-4 and CXCL10 were newly identified
DEGs that may contributed to tumor suppression.
Subsequently, we have built the pathways interaction
network to perform deep analysis. Through analyzing
the interactions among the significant pathways, it was
obvious Wnt signaling pathway, focal adhesion and
cytokine-cytokine receptor interaction were the most
important pathways involved in the function of CIKIL-15
Figure 2 Clustering of differentially expressed genes in CIKIL-15 and CIKIL2 and multiple DEGs involved GO terms. The genes included for
further analysis were labeled with red line by the sides of their gene symbols.
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cated at the centers of each clusters and showed the most
interactions with their surrounding pathways (the most
arrows toward them). The results suggested that Wnt4 signaling pathway and focal adhesion be the key bio-
logical events of CIKIL-15 cell proliferation, and cytokine-
cytokine receptor interaction be the dominant element in
CIKIL-2 cells in acquisition of tumor cytotoxic capacity.
Figure 3 Significant gene ontology analysis of DEGs in CIKIL-15 and CIKIL-2. (A) Significant GO terms of CIKIL-15; (B) Significant GO terms of
CIKIL-2. P value < 0.01 for all significant GO terms.
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pathways may play important roles in the distinct func-
tions of CIKIL-15 and CIKIL-2.
Differentially expressed genes act network
After functional analysis, it is important to explore the
relationships among these DEGs. According to KEGGdatabase, we built the act network of genes based on the
relationships between them including activation\binding,
expression, inhibition and compound. In this gene inter-
action network, CXCL10, CXCL9, CCL22, GLI2, WNT4,
CD80 and CTLA4 were in involved in pathways which
previously mentioned including Wnt signaling pathway,
Cytokine-cytokine receptor interaction and T cell signaling
Table 2 Up-regulated genes related with functions and phenotypes of CIKIL-15
Gene symbol Description Log2FC P value FDR Go Term
Wnt 4 Protein Wnt-4 1.10 3.61 × 10−4 7.28 × 10−3 Regulation of cell-cell adhesion; Wnt signaling pathway;
immature T cell proliferation in thymus; positive regulation
of focal adhesion assembly; T cell differentiation in thymus;
cell differentiation; cell-cell signaling; negative regulation of
apoptotic process; positive regulation of transcription,
DNA-templated
IL21R Interleukin 21 receptor 1.17 2.53 × 10−4 5.53 × 10−3 Interleukin-21-mediated signaling pathway; natural killer cell
activation; cytokine-mediated signaling pathway
DTX4 E3 ubiquitin-protein ligase 2.65 2.02 × 10−3 2.82 × 10−2 Regulation of type I interferon production; positive regulation
of type I interferon production; Notch signaling pathway;
innate immune response; protein ubiquitination
ICAM4 Intercellular adhesion molecule 4 1.90 1.46 × 10−4 3.51 × 10−3 Cell adhesion; cell-cell adhesion; regulation of immune response
PDGFD Platelet-derived growth factor D 1.65 2.38 × 10−5 8.11 × 10−4 Platelet-derived growth factor receptor signaling pathway;
cellular response to amino acid stimulus; multicellular
organismal development; regulation of peptidyl-tyrosine
phosphorylation; positive regulation of cell division
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protein) functioned as transcription factor which involved
in the expression of protein Wnt 4 in CIKIL-15. Again,
the interaction between CD80 and CTLA-4 has been
highlighted in CIKIL-2. After stimulation of IL-2, CD80
were up-regulated and interacted with CD28 providing
costimulation signal for T cell activation and prolifera-
tion. However, negative feedback has been turned on
through up-regulating the expression of CTLA4 which
bound to CD80 providing inhibitory signal instead of
CD28. Moreover, we also have noticed that CXCL10,
CCL22 and CXCL9 were associated with CCR1. TheTable 3 Up-regulated genes related with functions and pheno
Gene symbol Description Log2FC P value
CTLA4 Cytotoxic T-lymphocyte-associated
protein 4
1.01 1.64 × 10−3
CD80 CD80 antigen 1.03 1.11 × 10−3
TNFSF10 Tumor necrosis factor ligand
superfamily member 10
1.24 7.02 × 10−18
CD40L CD40 ligand 2.08 2.32 × 10−6
IRF7 Interferon regulatory factor 7 1.08 3.12 × 10−5association among these genes may be related with
anti-tumor activity and CIK cell recruitment.
Gene co-expression network
Alternatively, we performed the gene co-expression net-
work analysis between DEGs in CIKIL-15 and CIKIL-2 to
highlight groups of DEGs in synergy which may participate
in biological processes resulted in phenotypic changes
[31,32]. Among DEGs of CIKIL-15, we showed that the ex-
pression levels of IL21R (Interleukin 21 receptor), ENPP3
(Ectonucleotide pyrophosphatase/phosphodiesterase 3) and
TXNIP (Thioredoxin interacting protein) were positivelytypes of CIKIL-2
FDR Go terms
2.38 × 10−2 Immune response; negative regulation of regulatory
T cell differentiation; negative regulation of B cell
proliferation; T cell costimulation; B cell receptor
signaling pathway; cellular response to DNA damage
stimulus; positive regulation of apoptotic process
1.75 × 10−2 Innate immune response; positive regulation of GMCSF
biosynthetic process; positive regulation of T-helper
1 cell differentiation; T cell activation; regulation of
interleukin-2 biosynthetic process; T cell costimulation
4.45 × 10−15 Immune response; activation of cysteine-type endopeptidase
activity involved in apoptotic process regulation of extrinsic
apoptotic; signaling pathway in absence of ligand; apoptotic
process; positive regulation of extrinsic apoptotic signaling
pathway; positive regulation of release of cytochrome c from
mitochondria; apoptotic signaling pathway; positive regulation
of cysteine-type endopeptidase activity involved in apoptotic
process; positive regulation of apoptotic process
1.18 × 10−4 Immune response; inflammatory response; immunoglobulin
secretion; positive regulation of endothelial cell apoptotic
process; B cell proliferation; positive regulation of
interleukin-12 production; leukocyte cell-cell adhesion
1.02 × 10−3 Innate immune response; inflammatory response; positive
regulation of type I interferon-mediated signaling pathway;
positive regulation of type I interferon production; toll-like
receptor signaling pathway
Figure 4 Pathway enrichment analysis of DEGs based on KEGG. (A) Enriched pathways in CIKIL-15; (B) Enriched pathways in CIKIL-2; (C) Pathways
interaction network of CIKIL-15 and CIKIL-2, Red circles represent enriched pathways in CIKIL-15; Green circle represent enriched pathways in CIKIL-2.
Figure 5 Gene Act network analysis. Red circles represent up-regulated
genes in CIKIL-15; Green circles represent up-regulated genes in CIKIL-2.
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mune response (Figure 6A). Moreover, we also found a
group of genes that related with immune response includ-
ing IFI44 (Interferon-induced protein 44), FOXP3 (Fork-
head box P3), IF44L (Interferon-induced protein 44-like),
LY9 (T-lymphocyte surface antigen Ly-9) and IFI27 (Inter-
feron, alpha-inducible protein 27) in CIKIL-15 (Figure 6A).
It was obvious that a cluster genes related with cell prolifer-
ation and apoptosis including PDGFD (Platelet-derived
growth factor D), PHLDA1 (PHLDA1 protein), DSCC1
(Sister chromatid cohesion protein), S100A8 (Protein S100-
A8), DST (Bullous pemphigoid antigen 1) and EIF2AK2
(EIF2AK2 protein) were correlated in CIKIL-15 (Figure 6A).
In CIKIL-2, three pairs of genes with similar expression
profiles were found to be involved in type I interferon
signaling pathway (MX1/USP18; MX2/OAS1; IFT1/
IFT3) (Figure 6B). Interestingly, the expression pattern
of T cell activation negative regulator Foxp3 was
Figure 6 Gene co-expression network analysis. (A) CIKIL-15; (B) CIKIL-2; Degree in different color is defined as the link numbers one node has
with the other. The Pearson Correlation of each pair of genes were calculated from these three independent samples.
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CIKIL-2 (Figure 6B).
Validation of representative genes by qRT-PCR
We have examined the expression profiles of DEGs
which were referred in Table 2 and Table 3. The resultsof qRT-PCR have indicated that the expression profiles
of DEGs in CIKIL-15 and CIKIL-2 were consistent with
RNA-seq except for TNFSF10 (Figure 7). Notably, the
expression level of Wnt 4 in CIKIL-15 was over 3 fold of
those in CIKIL-2. However, TNFSF10 in CIKIL-2 were
slightly higher than CIKIL-15 (p>0.05). Therefore, TNFSF10
Figure 7 qRT-PCR validation of relative expression levels of representative DEGs. (A) DEGs in CIKIL-15; (B) DEGs in CIKIL-2; the expression
levels of corresponding genes were normalized by β-actin. The results were means and SEMs, representative of nine independent samples. (P < 0.05
in all DEGs except TNSF10).
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of CIKIL-2.
Discussion
Although clinical trials of CIK cells in cancer therapy
were widely performed in China, fewer studies on mo-
lecular mechanism of their anti-tumor function were ob-
served [33,34]. The pioneering work of CIK cells was
performed by Schmidt-Wolf from Stanford. The authors
indicated that CIK cells were a subset of non-MHC-
restricted T cells expressing both CD3 and CD56, and
CIK cells showed potent cytotoxicity against a variety of
tumor cells [2]. The efficiency of CIK cells preparation is
dependent on T cell proliferation and cytolytic activity
against tumor. To generate CIK cells with high quality,
cytokines such as IL-1, IL-7, IL-15 and IL-12 have been
employed instead of IL-2 or in combination with IL-2
[4]. Of these cytokines, IL-15 is widely tested in CIK
cells preparation against several tumor cells. In this
study, the results have indicated that CIKIL-15 exhibit
enhanced proliferation capacity than CIKIL-2, whereas,
CIKIL-2 showed more efficient cytotoxic effect againsttumor cells than CIKIL-15. Consistently, the results from
transcriptome analysis have shown corelationship with
their functional characteristics.
IL-15 is a pleiotropic cytokine which promote T cells
and NK cells proliferation and survival [35,36]. To better
elucidate the mechanism of increased proliferation cap-
acity induced by IL-15, we have found that Wnt 4 and
PDGFD which were correlated with cell proliferation
were up-regulated in CIKIL-15. Wnt signaling pathway is
widely involved in cell proliferation and differentiation
[37]. It has been reported that Wnt agonist promoted
mouse muscle cell proliferation, and specific silencing
RNA knockdown of Wnt 4 significantly reduced muscle
cell proliferation [38]. Moreover, study showed that the
expression of Wnt 4 was required for proliferation of
cells in mouse coelomic epithelium [39]. By pathway
interaction analysis, we have found that Wnt signaling
pathway is located at the center of the network, which
got the most interactions with other pathways. There-
fore, we suggested that Wnt signaling be one of the most
important pathways which contributed to the improved
proliferation capacity of CIKIL-15. Except for Wnt 4,
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regulates several cellular processes including cell prolifer-
ation, apoptosis and transformation [40]. Over-expression
of PDGFD in mouse or human breast cancer cell signifi-
cantly increased cell proliferation while silencing PDGFD
expression decreased proliferation and increased apoptosis
[41]. Studies have indicated that PDGFD promoted cell
proliferation by increasing DNA binding capacity of
NF-κB and down-regulation of PDGFD inhibit tumor
invasion through inactivation of Notch-1 and NF-κB
signaling [42]. Therefore, the up-regulation of Wnt 4
and PDGFD may be responsible for enhanced cell pro-
liferation of CIKIL-15.
Additionally, we also have found important evidence
which may inhibit the proliferation of CIKIL-2. By differ-
entiated expressed genes and gene act network analysis,
we found that CTLA4 and CD80 were up-regulated in
CIKIL-2. These two proteins can interact with each other
to provide inhibitory signal during T cell activation [43].
In the generation of CIKIL-2, OKT3 and IL-2 were sus-
tainedly presented in the culture system. However, IL-2
mediated activation-induced cell death (AICD) occurred
during the following culture [7]. Consistently, our previ-
ous phenotypic study of CIKIL-2 have showed that the
cells subset of CD3+CD28+ was increasing in the first
several days while significantly decreased since the 7th
day of culture (Data not shown). These results demon-
strated that the interaction between CTLA4 and CD80
may lead to inactivation of CD3+CD28+ T cell and in-
hibit proliferation of CIKIL-2. The inhibitory signal from
ligation of CTLA4 to CD80 is the negative feedback to
IL-2 stimulation of CIK cells. Comprehensively, not only
up-regulated Wnt 4 and PDGFD but also activation in-
hibitory signal from CTLA4 and CD80 in CIKIL-2 has re-
sulted in the enhanced proliferation capacity of CIKIL-15.
We suggest that supplement with cytokines or mAb
which down-regulates the inhibitory signal from CTLA4
and CD80 facilitate proliferation of CIKIL-2 production.
The most important of characteristic of CIK cell is cyto-
lytic activity against tumor. In vitro, CIKIL-2 cells have
shown more efficient tumor cytotoxicity than CIKIL-15.
The expression of CD40LG and IFR7 were up-regulated
in CIKIL-2. CD40LG, which is the ligand of CD40, has
shown great potentials in cancer therapy [44]. It has been
reported that CD40 is expressed in nearly all B cell malig-
nancy and many solid tumors [45]. The ligation of CD40
on the surface of tumor cells inhibits the growth of tumor
and induces apoptosis [46]. Besides CD40LG, IFN-β has
also been found to play critical role in anti-tumoral im-
mune response [47]. Interestingly, Moschonas has indi-
cated that stimulation of CD40 by its ligand has promoted
the expression of IFN-β through the binding IRF7 to its
promoter. IRF7 is a transcriptional factor which regulates
the expression of type I interferon [48]. Silencing of IRF7pathways in breast cancer accelerated bone metastasis
through immune escape [49]. Thus CD40LG and IFR7
may work synergically to improve the tumor cytotoxic ef-
fect of CIKIL-2.
On the other hand, the expression of DTX4 was up-
regulated in CIKIL-15 which positively regulated the
production of type I interferon through NLRP4 [50].
Moreover, the expression of IL-21R whose ligand is in-
volved in natural killer cell was also increased in
CIKIL-15. Paradoxically, the up-regulation of PDGFD
in CIKIL-15 not only could promote the proliferation of
CIKIL-15 cells but also promote tumor cells survival
through cell and cell interaction in tumor cytotoxic
assay. PDGFs are composed of four different polypep-
tide chains (PDGF A-D). It has been reported that
PDGFD was deregulated in most of human malignancies
with up-regulated expression in solid tumors [51]. The
factor interacts with PDGFR-β and activates downstream
signaling phosphatidylinositol 3-kinase (PI3K)/AKT, re-
sulted in tumor progression. Moreover, Li et al. reported
that PDGFD is a potent transformation growth factor for
NIH/3 T3 which increased the cell proliferation rate [52].
We suggested that up-regulated PDGFD is a double-
edged sword in CIKIL-15. Because it favored the prolifera-
tion of CIKIL-15 cells during preparation, while it may also
promoted the survival and proliferation of tumor cells
when CIK cells were in contact with tumor cells.
Conclusions
In this study, deep sequencing was performed to analyze
the different gene expression profiles of CIKIL-2 and
CIKIL-15 for the first time. By advanced bioinformatic
analysis of DEGs, we found that cell proliferation pro-
moting function was dominant in CIKIL-15 involving
Wnt signaling pathway and focal cell adhesion. In CIKIL-2,
type I interferon signaling pathway and cytokine-cytokine
receptor interactions were dominant. Through our find-
ings, we have preliminarily elucidated the cells prolifera-
tion and acquisition of tumor cytotoxicity mechanism of
CIKIL-15 and CIKIL-2. Better understanding of these mech-
anisms will help to generate novel CIK cells with greater
proliferation potential and improved tumor cytolytic
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